Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035.

Viking Therapeutics, Inc.'s VK2735 has potential as a GLP-1 for obesity amid Pfizer's exit, but competition and financing ...

Skye shares surge after new data shows nimacimab reduces weight over 30% with tirzepatide, with stable potency and promising ...

XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic benefits through a unique fat-blocking mechanism. However, its high ...

XENICAL remains a well-recognized option for obesity management, offering clinically significant weight loss and metabolic ...

GLP-1 receptor agonists and SGLT2 inhibitors are associated with a lower risk of dementia, suggesting these drugs may have a ...

Viking Therapeutics (VKTX) stock receives a Neutral rating at Goldman Sachs due to intense competition in its targeted ...

Historical trends and future projections of the number of people with overweight and obesity suggest alarming parallel ...

Novo Nordisk has bought into the “triple G” idea, gaining a GLP-1/GIP/glucagon triple agonist from China’s United Laboratories for up to $2 billion (1). In addition, AstraZeneca is committing up to ...

Additionally, Novo Nordisk and American biotech Lexicon have united to ... China-based United Biotechnology in an exclusive license agreement for UBT251, a triple agonist of GLP-1, GIP, and glucagon ...

Danish biopharma powerhouse Novo Nordisk is taking another bold move ... Novo picked up the new triple agonist, UBT251, from China-based United Biotechnology. The candidate, which is still in ...

Novo Nordisk has signed a deal worth up to $1bn with Lexicon Pharmaceuticals for the exclusive global rights to oral therapy LX9851.